DE3856059D1 - Peptid-Determinante mit Einfluss auf die Immunität - Google Patents

Peptid-Determinante mit Einfluss auf die Immunität

Info

Publication number
DE3856059D1
DE3856059D1 DE3856059T DE3856059T DE3856059D1 DE 3856059 D1 DE3856059 D1 DE 3856059D1 DE 3856059 T DE3856059 T DE 3856059T DE 3856059 T DE3856059 T DE 3856059T DE 3856059 D1 DE3856059 D1 DE 3856059D1
Authority
DE
Germany
Prior art keywords
amino acid
motif
followed
charged
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3856059T
Other languages
English (en)
Other versions
DE3856059T2 (de
Inventor
Lawrence Steinman
Scott Zamvil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22200262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3856059(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of DE3856059D1 publication Critical patent/DE3856059D1/de
Application granted granted Critical
Publication of DE3856059T2 publication Critical patent/DE3856059T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE3856059T 1987-08-17 1988-08-17 Peptid-Determinante mit Einfluss auf die Immunität Expired - Fee Related DE3856059T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8669487A 1987-08-17 1987-08-17

Publications (2)

Publication Number Publication Date
DE3856059D1 true DE3856059D1 (de) 1997-12-11
DE3856059T2 DE3856059T2 (de) 1998-07-16

Family

ID=22200262

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3856059T Expired - Fee Related DE3856059T2 (de) 1987-08-17 1988-08-17 Peptid-Determinante mit Einfluss auf die Immunität

Country Status (7)

Country Link
EP (2) EP0805162A1 (de)
JP (1) JPH01131124A (de)
AT (1) ATE159952T1 (de)
CA (1) CA1340012C (de)
DE (1) DE3856059T2 (de)
ES (1) ES2109217T3 (de)
GR (1) GR3025673T3 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988010120A1 (en) † 1987-06-24 1988-12-29 Brigham And Women's Hospital Treatment of autoimmune diseases by oral administration of autoantigens
US5869054A (en) * 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US6645504B1 (en) 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
US5641474A (en) * 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US6039947A (en) * 1987-06-24 2000-03-21 Autoimmune, Inc. Peptides derived from immunodominant epitopes of myelin basic protein
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US5547669A (en) 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
US6066621A (en) * 1989-12-10 2000-05-23 Yeda Research And Development Co. Ltd. Synthetic peptides for the treatment of myasthenia gravis
US6036957A (en) * 1990-03-30 2000-03-14 Autoimmune, Inc. Suppression of T-cell proliferation using peptide fragments of myelin basic protein
HUT69942A (en) * 1990-10-15 1995-09-28 Brigham & Womens Hospital Treatment of autoimmun diseases by oral administration of autoantigenes
US5652211A (en) * 1991-02-11 1997-07-29 Biosynth S.R.L. Peptides for neutralizing the toxicity of Lipid A
US5371186A (en) * 1991-02-11 1994-12-06 Biosynth S.R.L. Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6329499B1 (en) 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
WO1996026961A2 (en) * 1995-02-28 1996-09-06 National Jewish Center For Immunology And Respiratory Medicine Peptidyl compounds comprising an itim motif which regulate hematopoietic function and their use
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
CN1301756A (zh) * 1999-12-29 2001-07-04 复旦大学 一种新的多肽——髓磷脂p0蛋白14和编码这种多肽的多核苷酸

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988010120A1 (en) * 1987-06-24 1988-12-29 Brigham And Women's Hospital Treatment of autoimmune diseases by oral administration of autoantigens

Also Published As

Publication number Publication date
JPH01131124A (ja) 1989-05-24
DE3856059T2 (de) 1998-07-16
GR3025673T3 (en) 1998-03-31
EP0304279B1 (de) 1997-11-05
EP0304279A3 (de) 1990-05-16
EP0805162A1 (de) 1997-11-05
EP0304279A2 (de) 1989-02-22
CA1340012C (en) 1998-08-25
ES2109217T3 (es) 1998-01-16
ATE159952T1 (de) 1997-11-15

Similar Documents

Publication Publication Date Title
DE3856059D1 (de) Peptid-Determinante mit Einfluss auf die Immunität
IT1153265B (it) Polipeptidi contenenti la sequenza degli amminoacidi dell'interferone umano immune (interferone umano gamma), relativi veicoli di espressione, loro procedimento di preparazione, composizioni farmaceutiche contenenti tali polipeptidi
DK601786A (da) Hidtil ukendte prokoagulationsproteiner
ATE417925T1 (de) Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen
NZ218332A (en) Il-4(interleukin-4), recombinant production, dna, vectors and pharmaceutical composition
ZA8860B (en) Pancreatic secretory trypsin inhibitor and variants thereof produced by a recombinant host,process,expression vector and recombinant host therefor and pharmaceutical use thereof
PT85977A (en) Process for the preparation of human apolipoprotein ai and their variant forms by recombinant dna methods
IL81018A (en) Fusion proteins comprising small fragments of human interleukin-2 as ballast,process for its preparation and genes,vectors and transformed host containing said fragments and used in the process
ZA861482B (en) Polypeptides complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known
FI97299C (fi) Menetelmä kimeerisen transformoivan beta-kasvutekijän valmistamiseksi
ES2009588A6 (es) Un metodo para la preparacion de un polipeptido.
EP0177814A3 (de) Antikörper gegen Peptide und ihre Verwendung zum Nachweis von Onkogene-Produkten
KR880701073A (ko) 제조합 dna 기법에 의해 생성된 민악티빈
ATE315646T1 (de) Leukocyten-aktivierender faktor
DK0779297T3 (da) Antigene peptider med glycinsubstitutioner
DK210288D0 (da) Overproduktion af exocelllulaere proteiner
ATE91303T1 (de) Verfahren zur herstellung von peptiden durch spezifische spaltung von gentechnisch gewonnenen fusionsproteinen mit collagenasen.
DK547486A (da) Peptider samt praeparater indeholdende disse

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee